GLP-1 receptor agonists have been widely used and proven to improve cardiovascular clinical outcome in patients with acute myocardial infarction (NSTEMI and STEMI) treated with PCI [59, 60]. This evidence concerns the gene GLP1R and acute myocardial infarction.